Table 3 Progression-free survival – naïve and MAIC (base-case and sensitivity) analyses
|  | Naïve | Base-case analysis | Sensitivity analysis |
|---|---|---|---|
Axitinib (AXIS) vs. cabozantinib (METEOR) | |||
 Axitinib, median (95% CI) PFS, months | 4.8 (4.5–6.5) | 6.5 (4.7–10.4) | 4.8 (4.2–6.7) |
 Cabozantinib, median (95% CI) PFS, months | 9.1 (6.4–9.4) | 9.1 (6.4–9.4) | 9.1 (6.4–9.4) |
 aHR (95% CI) | – | 1.15 (0.82–1.63) | 1.39 (1.00–1.92) |
Axitinib (AXIS) vs. everolimus (METEOR) | |||
 Axitinib, median (95% CI) PFS, months | 4.8 (4.5–6.5) | 6.5 (4.7–11.0) | 6.5 (4.6–7.8) |
 Everolimus, median (95% CI) PFS, months | 3.7 (3.5–4.4) | 3.7 (3.5–4.4) | 3.7 (3.5–4.4) |
 aHR (95% CI) | – | 0.53 (0.36–0.80) | 0.63 (0.45–0.88) |